New combo therapy targets hard-to-treat cancers in early trial
NCT ID NCT04388852
First seen Nov 21, 2025 · Last updated May 01, 2026 · Updated 20 times
Summary
This early-phase study tests a new drug (DS3201) combined with an immunotherapy (ipilimumab) in 65 people with advanced prostate, bladder, or kidney cancer that has spread. The main goals are to find the safest dose and check side effects. Researchers hope this combination can help control the cancer by blocking tumor growth and boosting the immune system.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IVB PROSTATE CANCER AJCC V8 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.